Our findings extend previous reports of analgesic effects of Trk inhibitors in non-malignant skeletal and bone cancer pain17, 24 and indicate that analgesic effects of Trk inhibition might be mediated specifically by TrkA. This evidence concerns the gene NTRK1 and bone neoplasm.